Zydus Lifesciences LimitedNSE: ZYDUSLIFE

Press Release Jan 18 2025

· Issued by Zydus Lifesciences Limited

Filed with NSE · · 4 pages · English

Release

Zydus Lifesciences Limited has informed the Exchange regarding a press release dated January 18, 2025, titled "Zydus Lifesciences receives approval from USFDA to conduct Phase II(b) clinical trial for Usnoflast, a novel oral NLRP3 inflammasome inhibitor in patients with Amyotrophic Lateral Sclerosis (ALS)".

Zydus Lifesciences Limited on 6ix

Earlier from Zydus Lifesciences

Later from Zydus Lifesciences

All Zydus Lifesciences news releases